Acute Leukemias VIII: Prognostic Factors and Treatment Strategies

ISBN-13: 9783642621093 / Angielski / Miękka / 2012 / 724 str.

T. Buchner; W. Hiddemann; B. Wormann

Opis

Since 1987 Acute Leukemias (AL) has regularly reported on the state of the art in the rapidly growing, successful and exciting field of biology and management of these diseases. In this volume large multicenter clinical trials again form the solid basis for the investigation of leukemic cell biology, the detection of biologic subgroups, their differential response to alternative treatment strategies and the further development of therapy. In particular, this volume addresses mechanisms of chromosomal translocations and transcription factors, risk-adapted treatment strategies, differentiation therapy, secondary AL, special aspects in older patients, and adoptive immunotherapy. Besides the antileukemic approaches, supportive treatment with new antimicrobial substances and growth factors is updated. As a forum of worldwide activities in the field of AL this volume contains both exhaustive overviews on major clinical issues and preliminary data and hypotheses not previously published.

Spis treści

Mechanisms of Chromosomal Translocation Breakpoints.- Hematologic Malignancies Following Organ Transplantation.- Molecular Cytogenetic Characterization of a Critical Region in Bands 7q35-q36 Commonly Deleted in Malignant Myeloid Disorders.- olecular Characterization of the Translocation (10;11)(pl3;ql4): MLL and CALM are Fused to AF10 in Morphologically Different Subsets of Acute Leukemia.- LL-Duplcations are Rare and Associated with Poor Prognosis in Acute Myeloid Leukemia.- Real-Time RT-PCR for the Detection and Quantification of AML1/MTG8 Fusion Transcripts in Patients with t(8;21) Positive AML.- Combined Cytogenetic, FISH and RT-PCR Technique in Detection of t(15; 17) and Monitoring of Minimal Residual Disease in Acute Promyelocytic Leukemia.- RT-PCR in Diagnostics and Monitoring of Acute Myeloid.- Chromosome Aberrations in Primary and Secondary Acute Myeloblastic Leukemia.- Are there Two Main Categories of de Novo Acute Myeloid Leukemias with a Normal Karyotype?.- Asynchronous Expression of AC133 on CD34-Negative Leukemic Blast Cells in Childhood B-Cell Precursor ALL.- Expression of AC133 in Childhood Acute Leukemia.- CD10 Expression in T-Lineage Adult Acute Lymphoblastic Leukemia.- Acute Lymphoblastic Leukemia in Childhood with an Unusual Immunophenotype(CD7+/CD56+/CD33+).- Expression of IGFBP-rP2/CTGF is Specific for Malignant Lymphoblasts of Children with Acute Lymphoblastic Leucemia (ALL).- NM23-H1 Protein Expression as a New Prognostic Factor in Acute Lymphoblastic Leukemia.- Monitoring of Wilms’ Tumor Gene Transcription in Leukemia Patients.- Effect of Mutationally Activated Ras on the Ras to MAP Kinase Signaling Pathway and Growth Inhibition of Myeloid Leukemia Cells by Inhibitors of the MAP Kinase Cascade.- C-Jun is a JNK-Independent Coactivator of the PU.1 Transcription Factor.- CD7+ and CD56+ Acute Myelogeneous Leukemia is a Distinct Biologic and Clinical Disease Entity.- The Role of Apoptosis in the Course of Acute Leukemia in Children.- Evaluation of Spontaneous and Therapeutically Induced Apoptosis in Childhood Leukemias.- Involvement of BCL-2 and Bax in the IL-7-Induced Inhibition of Spontaneous Apoptosis in Childhood T-ALL.- Analysis of the Apoptotic Signal Transduction Cascade and New Differentially Expressed Genes in Drug Resistant and Sensitive Hematopoetic Cell Lines.- Transforming Activity of Flt3 in 32D Cells.- Evidence of Angiogenesis in Acute Myeloid Leukemia.- Significance of AC133 and CD34 Expression on Acute Myeloid Leukemia Cells.- Heterogeneity in the Stem Cell Compartment of Newly Diagnosed.- Acute Myeloid Leukemia Analyzed by 4-Colour Immunofluorescence Validation of the IPSS and Other Scoring Systems in Patients with Primary MDS.- Although Patients with AML and Complex Aberrant Karyotype Can be Subdivided Into Different Subtypes by Cytogenetics, Prognosis is Equally Poor.- Pharmacokinetics of Idarubicin: Intracellular Events and Extracellular Concentrations.- Oral Idarubicin in Maintenance Therapy of Acute Myeloid Leukemia.- Phase I Study of Liposomal Daunorubicin (DaunoXome) in Relapsed and Refractory Acute Myeloid Leukemia.- Multi Centre Study of a Combination of Fludarabine Phosphate, Cytosine Arabinoside and Granulocyte Colony Stimulating Factor (FLAG) in Relapsed and Refractory Acute Myeloid Leukaemia and in De Novo RAEB-t.- Modulation of AraC by Fludarabine: Results of Salvage Therapy by AMLCG.- Colony Stimulating Factors in Myelodysplastic Syndromes.- Modulation of Ara-C Toxification by Fludarabine and Hydroxyurea in Leukemia Blasts.- Drug Monitoring of Doxorubicin in Children.- Pharmacokinetics of Daunorubicin Entrapped in Liposomes or Erythrocytes — Phase II Study in Refractory Acute Leukemias.- Drug Monitoring During Maintenance Therapy in Children with ALL.- Modulation of Glucocorticoid Resistance in Childhood Acute Lymphoblastic Leukemia; Preliminary Results.- In-Vitro Cellular Drug Resistance in Acute Non-Lymphoblastic.- Leukemia: Comparisons Between Adults and Children Prognostic Relevance of In-Vitro Drug Sensitivity Testing in Adult AML.- Antileukemic Effects of Buthionine Sulfoximine (BSO) (NSC 326231) In Vivo: A Pilot Study in Acute Myeloblastic Leukemia.- Dendritic Cells Generated out of Blasts from Patients with Acute Leukemia.- Generation of Leukemia-Derived Dendritic Cells from Patients with AML.- Dendritic Cells from AML Patients in Complete Remission are Capable to Present Antigen to Autologous T Lymphocytes.- Antibody Response to Neuraminidase of the Influenza Virus in Children with Acute Lymphoblastic Leukaemia Vaccinated against Influenza after Chemotherapy.- Expansion and Fibronectin-Enhanced Retroviral Transduction of Primary Human T Lymphocytes for Adoptive Immunotherapy.- Early Empiric Antifungal Treatment of Infections in Neutropenic Patients with Hematological Malignancies Comparing Fluconazole with Amphotericin B and 5-Flucytosine.- The Role of Newer Quinolones in the Management of Infections in Patients with Hematologic Malignancies.- Fungal Infections in Paediatric Haematology.- Empirical Antimicrobial Therapy of FUO and Proved Infections in Neutropenic Patients.- Multivariate Analysis of Prognostic Factors in Patients with Refractory and Relapsed Acute Myeloid Leukemia Undergoing Sequential High-Dose Cytosine Arabinoside and Mitoxantrone (S-HAM) Salvage Therapy: Significance of Cytogenetic Abnormalities.- Incidence of Central Venous Catheter (CVC)-Infections in Patients with Acute Leukemia.- Do we Need a Triple Antibiotic Therapy?.- Study of G-CSF Influences on CD10 and CD64 Distribution on Neutrophils in Leukemic Patients.- RHuGM-CSF (Molgramostim) in the Treatment of Children and Adolescents with Acute Myeloid Leukemia.- CCG Experience with the Augmented BFM Regimen.- Pharmacodynamics in Childhood Acute Lymphoblastic Leukemia.- The Late Effects of Prophylactic CNS Treatment.- The Use of PEG-Asparaginase in Leukemic Children with Prior Hypersensitivity to Native L-Asparaginase.- The Importance of MRI in Detection of Primary CSN Involvement in Leukaemic Children.- Treatment of Adult Acute Lymphoblastic Leukemia Long Term Results of a Prospective Study: LALA 87.- Results of Recent Clinical Trials in Acute Lymphoblastic Leukemia by the Cancer and Leukemia Group B.- Early Application of Anthracyclines in Adult Acute Lymphoblastic Leukemia (ALL).- Allogeneic Bone Marrow Transplantation for BCR-ABL Positive Acute Lymphoblastic Leukemia.- Preliminary Results of a Risk-Oriented Program for B-Lineage Adult Acute Lymphoblastic Leukemia (ALL): The Collaborative Italian Study 08/96.- Prognostic Factors in Philadelphia+/BCR-ABL+ Acute Lymphoblastic Leukemia.- High-Dose Cytarabine Combined to Mitoxantrone in the Treatment of Refractory and Relapsed Acute Lymphoblastic Leukemia.- SPLIT-Course High-Dose ARA-C Plus Idarubicin and Multidrug Blockade by short Cyclosporin-A Infusion for Refractory Acute Myeloid Leukemia.- Recent Genetic Studies of Adult Patients with Acute Myeloid Leukemia.- Performed by the Cancer and Leukemia Group B The Impact of Treatment on the Outcome of Cytogenetic Subgroups in Acute Myeloid Leukemia — Results of the German AML Cooperative Group.- High Dose Cytosine Arabinoside Combined with an Anthracycline as Remission Induction in Acute Myeloid Leukemia.- Comparison of the Efficacy of TAD-TAD and „7+3“ Regimens in Adult AML, the Role of Dose Intensity and Mdr-1 Gene Expression Stratification of Postremission Therapy in Patients with Acute Myeloid.- Leukemia ? 60 Years According to the Karyotype: Results of the German Multicenter Treatment Trials AML HD93 and AML HD98-A.- Phase 1 Trial of Docetaxel (Taxotere) for Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML).- Including Quality of Life as an Important End Point in Evaluating Intensive and Prolonged Treatment for Acute Myeloid Leukemia (AML).- The 10.000/?l Morning Trigger for Prophylactic Platelet Transfusion is Safe: Prospective Experience in 411 AML Patients.- Prognostic Factors and Patterns of Failure in Childhood Acute Myeloid Leukemia: Experience on Pediatric Oncology Group Study # 8821.- Early Response to Therapy is the Strongest Prognostic Factor in Childhood AML.- Long-Term Outcome and Prognostic Factors in Children’s Cancer Group Study 2891 for Children and Adolescents with Previously Untreated Acute Myeloid Leukemia and Myelodysplastic Syndrome.- Risk-Adapted Therapy and Randomization in Children with AML: Preliminary Results of Study AML-BFM 93.- Acute Myeloid Leukemia (AML) in Children: Results of the French Trials.- AML in Children: The Medical Research Council Data.- Preliminary Results of a Multicentre Therapy Study for the Treatment of Children and Adolescents with AML in the Ukraine.- IDA-FLAG - An Effective Reinduction Therapy for Poor Prognosis AML of Childhood - Report of a Multicenter Phase II Trial.- APL Biology.- Molecular Diagnosis and Monitoring of Acute Promyelocytic Leukemia:.- Updated Results of the Italian Gimema Group AU-Trans-Retinoic Acid Maintenance for Acute Promyelocytic Leukemia.- Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide.- Randomized Comparison of Sequential High-Dose Cytosine Arabinoside and Idarubicin (S-HAI) with or without Chemo-Modulation by Fludarabine in Refractory and Relapsed Acute Myeloid Leukemia.- Acute Promyelocytic Leukemia and Pregnancy.- Severe Laryngeal Edema in Acute Promyelocytic Leukemia under All-Trans Retinoic Acid.- ExtrameduUary Acute Promyelocytic Leukemia.- Chemotherapy and All-Trans Retinoic Acid in Patients >60 Years with Acute Myeloid Leukemia: First Results of the Multicenter Treatment Trial AML HD98-B.- Treatment of Older Patients with Acute Myeloid Leukemia (AML).- AML in the Elderly.- The EORTC-HOVON Approach to the Older Patient with AML: The Use of GM-CSF.- Therapy of Older Adults with AML: CALGB Studies.- Treatment of Older Adults with Acute Myelogenous Leukemia: Studies of the Eastern Cooperative Oncology Group (ECOG).- A Landmark Analysis of Survival by Response Category in Elderly Patients with Acute Myeloblastic Leukemia.- Intensive Chemotherapy Followed by Stem Cell Transplantation for the Treatment of Myelodysplastic Syndromes.- Secondary Leukemia or Myelodysplasia Treated by Bone Marrow Transplantation.- Comparison of Intensive Chemotherapy and Autologous Transplantation as Post Remission Therapy in Adult Acute Myeloid Leukemia. Update of the GOELAM 1 Trial.- Adoptive Immunotherapy of Acute Leukemia and Acute Phase Chronic Myeloid Leukemia after Allogeneic Bone Marrow Transplantation.- Shifting Towards Better Immunotherapy Rather Than More Intensive Chemoradiotherapy Using a Non-Myeloablative Approach in Patients with Leukemia.- Long-Term Results of Autologous Bone Marrow Transplantation as Late Intensification in AML.- Results of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-Risk MDS.- Dose Reduced Conditioning for Allogeneic Blood Stem Cell Transplantation from Sibling and Unrelated Donors in 51 Patients.- Analysis of Chimerism in the Early Posttransplantation Period in Cellular Subsets of Patients Undergoing Myeloablative and Non-Myeloablative (Metakine) Allogeneic Blood Stem Cell Transplantation (BSCT).- Somnolence Syndrome after Total Body Irradiation in Children with Bone Marrow Transplantation.- Ten Years of Autologous Stem Cell Transplantation in Acute Leukemia: Single Center Experience in 46 Patients.- Transplant Characteristics: Minimal Residual Disease and Impaired Megakaryocytic Colony Growth as Sensitive Parameters for Predicting Relapse in Acute Myeloid Leukemia.- 721.